Alzheimer’s Disease Treatment Market Value Will Exceed $13 Billion
The global market for Alzheimer’s Disease (AD) treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023, representing a Compound Annual Growth Rate (CAGR) of 10.50%, according to research and consulting firm GlobalData.
The company’s latest report, PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2023 – Event Driven Update, states that this increase, which will occur across nine major markets (9MM), namely the US, France, Germany, Italy, Spain, the UK, Japan, China, and India, will be driven by the launch of 15 new therapies, including several drug candidates that have the potential to modify the underlying cause of AD.
The increasing prevalence of AD and mild cognitive impairment across the 9MM, coupled with advances in diagnostic capability and increased social awareness of the disease, will contribute further to market growth.
Kyle S. Nicholson, PharmD, GlobalData’s Analyst covering Neurology, says disease-modifying treatments and novel symptomatic therapies with innovative mechanisms of action will enter the arena during the forecast period and become routinely used in care.
Nicholson explains “Following the anticipated approval and launch of first-in-class BACE1 inhibitors and passive immunotherapies in 2018 and 2019, respectively, the AD treatment market will undergo rapid expansion, as several blockbuster drugs are expected to come from these two potentially disease-modifying therapeutic classes. The experimental monoclonal antibodies (mAbs), Biogen’s aducanumab, Eli Lilly’s solanezumab and Roche’s gantenerumab and crenezumab, will compete with the BACE1 inhibitors, Merck’s MK-8931 and AstraZeneca/Eli Lilly’s AZD-3293, as both treatment approaches are designed to prevent the formation of senile amyloid plaques.”
The analyst adds that the symptomatic therapies in the pipeline, such as Lundbeck’s LuAE-58054 and Forum’s EVP-6124, will also gain market share as the prevalence of symptomatic AD increases throughout the 9MM by 2023. GlobalData anticipates that Namenda, Aricept and Exelon, the current AD drug market leaders with cumulative sales of $4.3 billion in 2013, will maintain strong shares throughout the forecast period. However, their combined sales will fall annually from 2015, with Namenda and Aricept having recently lost patent exclusivity.
This report provides annualized Alzheimer’s Disease (AD) therapeutics market revenue, annual cost of treatment and usage patterns from 2013 and forecast for ten years to 2023, across the nine major markets of the US, France, Germany, Italy, Spain, the UK, Japan, China, and India. Key topics covered include strategic competitor assessment, unmet needs, clinical trial mapping and implications for the AD treatment market.
It was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Its research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries. For more information, please contact our Press Office on +44 (0)1204 543 537 or at email@example.com. Gain access to our latest press releases and expert analysis on developments in your industry. Subscribe to our RSS feed for the Healthcare sector, or connect with us on: Facebook | LinkedIn | Twitter
Total Page Views: 8427